IN2014CN04055A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04055A
IN2014CN04055A IN4055CHN2014A IN2014CN04055A IN 2014CN04055 A IN2014CN04055 A IN 2014CN04055A IN 4055CHN2014 A IN4055CHN2014 A IN 4055CHN2014A IN 2014CN04055 A IN2014CN04055 A IN 2014CN04055A
Authority
IN
India
Prior art keywords
proportion
composition
increased
disease
treat
Prior art date
Application number
Other languages
English (en)
Inventor
Thomas W Boileau
Jennifer Brulc
Ravindranath Sreedhar Menon
Original Assignee
Gen Mills Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Mills Inc filed Critical Gen Mills Inc
Publication of IN2014CN04055A publication Critical patent/IN2014CN04055A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25Synthetic polymers, e.g. vinylic or acrylic polymers
    • A23L33/26Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10Cereal-derived products
    • A23L7/117Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
    • A23L7/126Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3202Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IN4055CHN2014 2011-11-04 2012-11-01 IN2014CN04055A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555800P 2011-11-04 2011-11-04
PCT/US2012/063008 WO2013067146A1 (en) 2011-11-04 2012-11-01 Methods and compositions for modulating gastrointestinal bacteria to promote health

Publications (1)

Publication Number Publication Date
IN2014CN04055A true IN2014CN04055A (ru) 2015-10-23

Family

ID=48192757

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4055CHN2014 IN2014CN04055A (ru) 2011-11-04 2012-11-01

Country Status (11)

Country Link
US (1) US20150209383A1 (ru)
EP (1) EP2773357A4 (ru)
JP (1) JP2014532710A (ru)
KR (1) KR20140093252A (ru)
CN (1) CN104159588A (ru)
AU (1) AU2012332491A1 (ru)
BR (1) BR112014010660A2 (ru)
CA (1) CA2854398A1 (ru)
IN (1) IN2014CN04055A (ru)
MX (1) MX2014005433A (ru)
WO (1) WO2013067146A1 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3283087A4 (en) * 2015-04-14 2019-03-13 Ubiome Inc. METHOD AND SYSTEM FOR MICROBIOMEDIVED DIAGNOSTICS AND THERAPEUTICS FOR DISEASES OF THE ENDOCRINE SYSTEM
EP3294308A4 (en) 2015-05-14 2019-03-06 University of Puerto Rico PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN
GB201519088D0 (en) * 2015-10-28 2015-12-09 Metabogen Ab The use of bacteria formulations
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
JP6573639B2 (ja) * 2016-01-26 2019-09-11 富士フイルム株式会社 腸内細菌数抑制剤、食品、及び医薬品
WO2017159647A1 (ja) * 2016-03-14 2017-09-21 物産フードサイエンス株式会社 フィーカリバクテリウム属細菌増殖剤
EP3511406A4 (en) * 2016-09-06 2020-04-01 BGI Shenzhen FAECALIBACTERIUM LONGUM AND ASSOCIATED APPLICATION
KR20200010450A (ko) 2017-06-02 2020-01-30 굿것 에스.엘. 장내 세균 불균형의 치료에 사용하기 위한 포도 껍질
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP3466417A1 (en) * 2017-10-04 2019-04-10 Sorbonne Université Compounds for the prevention and treatment of glucose intolerance related conditions and obesity
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
CN109998112B (zh) * 2017-12-22 2024-05-14 奥地利商艾尔柏有限公司 红蝽杆菌纲促进肠道健康的用途
EP3752167A1 (en) * 2018-02-14 2020-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Polydextrose for the treatment of inflammatory diseases
WO2019216815A1 (en) * 2018-05-09 2019-11-14 Carbiotix Ab Method for measuring and improving gut health
CN112218646B (zh) * 2018-05-31 2024-06-11 深圳华大生命科学研究院 一种组合物及其应用
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
ES2763874B2 (es) * 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades
CA3153884A1 (en) * 2019-10-07 2021-04-15 Nikole KIMES Therapeutic pharmaceutical compositions
KR102174095B1 (ko) * 2019-12-11 2020-11-05 주식회사 에이치이엠 신규한 엔테로코커스 패시움 hem 200 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물
EP4333644A1 (en) * 2021-05-06 2024-03-13 Société des Produits Nestlé S.A. Compositions and methods using at least one of inositol, erythritol or sorbitol to enhance growth of faecalibacterium prausnitzii
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0394655A (ja) * 1989-09-06 1991-04-19 Otsuka Pharmaceut Co Ltd 栄養補給用組成物
JP4328473B2 (ja) * 2001-04-09 2009-09-09 雪印乳業株式会社 肥満予防改善飲食品
FI20020078A (fi) * 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
JP2003334025A (ja) * 2002-05-15 2003-11-25 Toyo Shinyaku:Kk 健康食品
DE60330781D1 (de) * 2002-08-06 2010-02-11 Danisco Anwendung von lactobacillus zur herstellung von exopolysacchariden in nahrungsmittel und pharmazeutische zusammensetzungen
GB0302872D0 (en) * 2003-02-10 2003-03-12 Univ Liverpool Treatment of inflammatory bowel disease
AU2008256938B2 (en) * 2007-05-23 2013-02-28 Tate & Lyle Ingredients Americas Llc Edible composition comprising a slowly digestible or digestion resistant oligosaccharide composition
GB0903016D0 (en) * 2009-02-23 2009-04-08 Univ Gent Method for alleviating intestinal problems and novel bacterial strains therefor
JP6077303B2 (ja) * 2009-05-07 2017-02-08 タト エ リル アングルディアント フランス ソシエテ パ アクシオンス シンプリフィエ アルファ−(1,2)−分岐アルファ−(1,6)オリゴデキストランを含有する組成物及びアルファ−(1,2)−分岐アルファ−(1,6)オリゴデキストランの製造方法

Also Published As

Publication number Publication date
CA2854398A1 (en) 2013-05-10
MX2014005433A (es) 2014-08-22
WO2013067146A1 (en) 2013-05-10
AU2012332491A1 (en) 2014-05-29
EP2773357A4 (en) 2015-08-26
BR112014010660A2 (pt) 2017-05-09
US20150209383A1 (en) 2015-07-30
KR20140093252A (ko) 2014-07-25
JP2014532710A (ja) 2014-12-08
EP2773357A1 (en) 2014-09-10
CN104159588A (zh) 2014-11-19

Similar Documents

Publication Publication Date Title
IN2014CN04055A (ru)
Li et al. Probiotic mixture of Lactobacillus plantarum strains improves lipid metabolism and gut microbiota structure in high fat diet-fed mice
Xu et al. Function of Akkermansia muciniphila in obesity: interactions with lipid metabolism, immune response and gut systems
Li et al. Sinapine reduces non-alcoholic fatty liver disease in mice by modulating the composition of the gut microbiota
Zou et al. Rice bran attenuated obesity via alleviating dyslipidemia, browning of white adipocytes and modulating gut microbiota in high-fat diet-induced obese mice
Zhou et al. Effects of medium-and long-chain triacylglycerols on lipid metabolism and gut microbiota composition in C57BL/6J mice
Zeng et al. Lotus seed resistant starch regulates gut microbiota and increases short-chain fatty acids production and mineral absorption in mice
Chen et al. Bamboo-shaving polysaccharide protects against high-diet induced obesity and modulates the gut microbiota of mice
Zhang et al. Changes in intestinal microbiota of type 2 diabetes in mice in response to dietary supplementation with instant tea or matcha
Liu et al. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice
Yuan et al. Punicic acid ameliorates obesity and liver steatosis by regulating gut microbiota composition in mice
Song et al. Dietary anthocyanin-rich extract of açai protects from diet-induced obesity, liver steatosis, and insulin resistance with modulation of gut microbiota in mice
Zhou et al. Gut microbiota might be a crucial factor in deciphering the metabolic benefits of perinatal genistein consumption in dams and adult female offspring
Kobyliak et al. Comparative experimental investigation on the efficacy of mono-and multiprobiotic strains in non-alcoholic fatty liver disease prevention
MX2012012777A (es) Agentes de union del receptor nuclear.
JP2008113671A5 (ru)
WO2010136900A3 (en) Methods of using krill oil to treat risk factors for metabolic disorders and obesity
Yang et al. Enhancing flora balance in the gastrointestinal tract of mice by lactic acid bacteria from Chinese sourdough and enzyme activities indicative of metabolism of protein, fat, and carbohydrate by the flora
Li et al. Crude polysaccharide extracted from Moringa oleifera leaves prevents obesity in association with modulating gut microbiota in high-fat diet-fed mice
Ji et al. Fermented Rosa roxburghii Tratt juice alleviates high-fat diet-induced hyperlipidemia in rats by modulating gut microbiota and metabolites
Aoki et al. Oral administration of the Aureobasidium pullulans-derived β-glucan effectively prevents the development of high fat diet-induced fatty liver in mice
Zhao et al. Selenium-enriched Bifidobacterium longum DD98 relieves metabolic alterations and liver injuries associated with obesity in high-fat diet-fed mice
RU2013128920A (ru) Способ ингибирования патогенов с использованием питательной композиции
Meng et al. Effect of dietary honeysuckle (Lonicera caerulea L.) supplementation on lipid metabolism, immunity and intestinal microbiota in grass carp (Ctenopharyngodon idellus)
WO2011087857A3 (en) Compositions and methods for treating obesity and diabetes